Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 4/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | HTR1D | P28221 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5926079 | 0.85 | HTR1A (0.54) | HTR1ADRD4HTR1DADRA1AHTR2B | |
| SCHEMBL5926176 | 0.80 | HTR1A (0.54) | HTR1ADRD2 | |
| SCHEMBL5926141 | 0.74 | KCNH2 (0.53) | HTR1AADRA1ADRD2 | |
| SCHEMBL7821489 | 0.74 | HTR1A (0.46) | HTR1ADRD2 | |
| SCHEMBL5926325 | 0.73 | DRD2 (0.48) | HTR1AADRA1ADRD2 | |
| SCHEMBL5926097 | 0.71 | HTR7 (0.56) | HTR1ADRD2 | |
| SCHEMBL5926085 | 0.71 | PIM1 (0.47) | HTR1ADRD4DRD2 | |
| SCHEMBL5926252 | 0.71 | HTR2A (0.53) | HTR1ADRD4DRD2 | |
| SCHEMBL5926059 | 0.70 | HTR1A (0.50) | HTR1ADRD4HTR1DADRA1AHTR2B | |
| SCHEMBL7818467 | 0.70 | HTR1A (0.47) | HTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060211703-A1 | Substituted alkyl-pyridazinones for the treatment of memory and learning malfunctions | EGIS GYOGYSZERGYAR RT. (HU) | 2006-09-21 | — | — | US | claimed |
| EP-1567159-A1 | SUBSTITUTED ALKYL-PYRIDAZINONES FOR THE TREATMENT OF MEMORY AND LEARNING MALFUNCTIONS | EGIS GYOGYSZERGYAR RT. (HU) | 2005-08-31 | — | — | EP | claimed |
| US-6930110-B2 | Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same | EGIS GYOGYSZERGYAR RT. (HU) | 2005-08-16 | — | — | US | claimed |
| EP-1430047-B1 | SUBSTITUTED ALKYLAMINOPYRIDAZINONE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 2005-02-09 | — | — | EP | claimed |
| US-20040242873-A1 | Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same | EGIS GYOGYSZERGYAR RT. (HU) | 2004-12-02 | — | — | US | claimed |
| EP-1430047-A1 | SUBSTITUTED ALKYLAMINOPYRIDAZINONE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Egis Gyogyszergyar Rt. (HU) | 2004-06-23 | — | — | EP | claimed |
| WO-2004043465-A1 | SUBSTITUTED ALKYL-PYRIDAZINONES FOR THE TREATMENT OF MEMORY AND LEARNING MALFUNCTIONS | EGIS Gyógyszergyár Rt. (HU) | 2004-05-27 | — | — | WO | claimed |
| WO-2003027097-A1 | SUBSTITUTED ALKYLAMINOPYRIDAZINONE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | EGIS Gyógyszergyár Rt. (HU) | 2003-04-03 | — | — | WO | claimed |
| US-20060211703-A1 | Substituted alkyl-pyridazinones for the treatment of memory and learning malfunctions | EGIS GYOGYSZERGYAR RT. (HU) | 2006-09-21 | — | — | US | disclosed |
| EP-1567159-A1 | SUBSTITUTED ALKYL-PYRIDAZINONES FOR THE TREATMENT OF MEMORY AND LEARNING MALFUNCTIONS | EGIS GYOGYSZERGYAR RT. (HU) | 2005-08-31 | — | — | EP | disclosed |
| US-6930110-B2 | Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same | EGIS GYOGYSZERGYAR RT. (HU) | 2005-08-16 | — | — | US | disclosed |
| EP-1430047-B1 | SUBSTITUTED ALKYLAMINOPYRIDAZINONE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 2005-02-09 | — | — | EP | disclosed |
| US-20040242873-A1 | Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same | EGIS GYOGYSZERGYAR RT. (HU) | 2004-12-02 | — | — | US | disclosed |
| EP-1430047-A1 | SUBSTITUTED ALKYLAMINOPYRIDAZINONE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Egis Gyogyszergyar Rt. (HU) | 2004-06-23 | — | — | EP | disclosed |
| WO-2004043465-A1 | SUBSTITUTED ALKYL-PYRIDAZINONES FOR THE TREATMENT OF MEMORY AND LEARNING MALFUNCTIONS | EGIS Gyógyszergyár Rt. (HU) | 2004-05-27 | — | — | WO | disclosed |
| WO-2003027097-A1 | SUBSTITUTED ALKYLAMINOPYRIDAZINONE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | EGIS Gyógyszergyár Rt. (HU) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242873-A1 | Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same | CYP3A5, CYP11B1, ADRA1D | HTR1A 39/4885DRD4 41/4885HTR1D 23/4885 |
| US-20060211703-A1 | Substituted alkyl-pyridazinones for the treatment of memory and learning malfunctions | CHRM1, CHRM2, CHRM5 | HTR1A 225/4885DRD4 101/4885HTR1D 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.